HBM Holdings Ltd Ordinary Shares HBMHF
Trading Information
- Previous Close Price
- $2.52
- Day Range
- $1.56–1.56
- 52-Week Range
- $1.56–2.54
- Bid/Ask
- $0.60 / $10,003.15
- Shares Outstanding
- 835.26M
- Market Cap
- $1.31B
- Volume/Avg
- 13,868 / 13,859
Key Statistics
- Price/Earnings (Normalized)
- 13.68
- Price/Sales
- 8.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 272
- Website
- https://www.harbourbiomed.com
Valuation
|
Metric
|
HBMHF
|
|---|---|
Price/Earnings (Normalized) | 13.68 |
Price/Book Value | 3.55 |
Price/Sales | 8.01 |
Price/Cash Flow | 17.65 |
Price/Earnings
HBMHF
Financial Strength
|
Metric
|
HBMHF
|
|---|---|
Quick Ratio | 5.07 |
Current Ratio | 5.17 |
Interest Coverage | 40.87 |
Quick Ratio
HBMHF
Profitability
|
Metric
|
HBMHF
|
|---|---|
Return on Assets (Normalized) | 22.23% |
Return on Equity (Normalized) | 31.46% |
Return on Invested Capital (Normalized) | 21.75% |
Return on Assets
HBMHF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|SLS#%By | LOCK|HV%yf | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|vdg>>>& | LOCK|z@cw | $83B | |||
| argenx SE ADR
ARGX
| LOCK|?<^D?#@ | LOCK|@p | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>#$qrX@Z | LOCK|CDfc | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%c#&!Bt | LOCK|&N> | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#R>$c>w | LOCK|wgC@ | $31B | |||
| Moderna Inc
MRNA
| LOCK|?x<@tz | LOCK|Jgj | $25B | |||
| Incyte Corp
INCY
| LOCK|B>?T&Lx | LOCK|S! | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|QVYSgZ& | LOCK|#gd | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|lX&^s& | LOCK|QS | $16B |
United States